CL2015002750A1 - Anticuerpos humanos pac1 - Google Patents

Anticuerpos humanos pac1

Info

Publication number
CL2015002750A1
CL2015002750A1 CL2015002750A CL2015002750A CL2015002750A1 CL 2015002750 A1 CL2015002750 A1 CL 2015002750A1 CL 2015002750 A CL2015002750 A CL 2015002750A CL 2015002750 A CL2015002750 A CL 2015002750A CL 2015002750 A1 CL2015002750 A1 CL 2015002750A1
Authority
CL
Chile
Prior art keywords
pac1
human antibodies
antibodies
human
pac1 human
Prior art date
Application number
CL2015002750A
Other languages
English (en)
Inventor
Cen Xu
Agnes Eva Hamburger
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2015002750A1 publication Critical patent/CL2015002750A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
CL2015002750A 2013-03-15 2015-09-15 Anticuerpos humanos pac1 CL2015002750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792678P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002750A1 true CL2015002750A1 (es) 2016-03-04

Family

ID=50439531

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002750A CL2015002750A1 (es) 2013-03-15 2015-09-15 Anticuerpos humanos pac1

Country Status (24)

Country Link
US (7) US9676851B2 (es)
EP (2) EP2970470B1 (es)
JP (3) JP6283408B2 (es)
KR (1) KR102215405B1 (es)
CN (1) CN105143267B (es)
AP (1) AP2015008732A0 (es)
AR (1) AR095611A1 (es)
AU (2) AU2014228924B2 (es)
CA (1) CA2906737C (es)
CL (1) CL2015002750A1 (es)
CR (1) CR20150575A (es)
EA (1) EA032830B1 (es)
ES (1) ES2770976T3 (es)
HK (2) HK1218554A1 (es)
IL (2) IL241382A0 (es)
MA (1) MA38478A1 (es)
MX (1) MX2015013181A (es)
PE (1) PE20151923A1 (es)
PH (1) PH12015502126A1 (es)
SG (1) SG11201507416WA (es)
TN (1) TN2015000425A1 (es)
TW (2) TWI636064B (es)
UY (1) UY35483A (es)
WO (1) WO2014144632A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
CA2982856A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SG11201808630WA (en) 2016-04-15 2018-10-30 Alder Biopharmaceuticals Inc Humanized anti-pacap antibodies and uses thereof
AR113022A1 (es) * 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap
SG11202003114UA (en) * 2017-10-04 2020-05-28 Amgen Inc Transthyretin immunoglobulin fusions
AU2018393073A1 (en) 2017-12-19 2020-07-02 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
JP7317016B2 (ja) 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド 抗ｌｒｐ５／６抗体及び使用方法
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
KR20200139720A (ko) 2018-04-02 2020-12-14 암젠 인크 에레누맙 조성물 및 이의 용도
EA202092464A1 (ru) 2018-04-12 2021-01-27 Эмджен Инк. Способы получения стабильных композиций на основе белков
AU2020304671A1 (en) 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
WO2023015298A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
ATE210680T1 (de) 1990-03-17 2001-12-15 Takeda Chemical Industries Ltd Antikörper gegen hypophysäre adenylatzyklase aktivierende peptid-pacap, hybridome und bestimmung von pacap
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
EP0618291A3 (en) 1993-02-26 1997-12-03 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US6462016B1 (en) 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
DE69941708D1 (de) 1998-07-20 2010-01-07 Ipsen Pharma Pacap-peptidanaloga
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20020155533A1 (en) 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004046330A2 (en) * 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
WO2004062684A2 (en) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
US20050129687A1 (en) 2003-11-03 2005-06-16 University Of Vermont And State Agricultural College Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
US20090215895A1 (en) 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
WO2008018472A1 (fr) * 2006-08-08 2008-02-14 Kyoto University Nouvel anticorps monoclonal et son utilisation
WO2009003489A1 (en) 2007-07-02 2009-01-08 Natimmune A/S CaOU-1 EPITOPE BINDING POLYPEPTIDES
WO2009033489A2 (en) 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
CN101434649B (zh) 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
SG10201406930UA (en) 2009-07-27 2014-11-27 Nocicepta Llc Methods For Treatment Of Pain
US20120191435A1 (en) * 2009-09-25 2012-07-26 Shanghai National Engineering Research Center Of Antibody Medicine Co., Ltd. Method of acquiring proteins with high affinity by computer aided design
MX2012007318A (es) 2009-12-22 2012-07-20 Novartis Ag Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
WO2011118739A1 (ja) * 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
US20140112926A1 (en) * 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
CN102936303A (zh) * 2011-08-15 2013-02-20 沈阳欧陆科技发展有限公司 一种高氯含量的氯化聚氯乙烯树脂的合成方法
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
MX2014014166A (es) 2012-05-21 2015-03-03 Genentech Inc Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica.
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
US9676851B2 (en) 2017-06-13
AU2019204980A1 (en) 2019-08-01
AR095611A1 (es) 2015-10-28
US10472417B2 (en) 2019-11-12
TWI636064B (zh) 2018-09-21
TW201522375A (zh) 2015-06-16
JP6443870B2 (ja) 2018-12-26
AU2014228924A9 (en) 2016-06-16
IL262804A (en) 2018-12-31
US10793631B2 (en) 2020-10-06
US20160039939A1 (en) 2016-02-11
EP3683237A1 (en) 2020-07-22
KR20150128982A (ko) 2015-11-18
UY35483A (es) 2014-08-29
JP2016514458A (ja) 2016-05-23
US20200172614A1 (en) 2020-06-04
JP2019024501A (ja) 2019-02-21
TW201902931A (zh) 2019-01-16
JP6283408B2 (ja) 2018-02-21
AP2015008732A0 (en) 2015-09-30
JP2018076373A (ja) 2018-05-17
CN105143267A (zh) 2015-12-09
AU2014228924B2 (en) 2019-04-18
WO2014144632A8 (en) 2015-12-30
WO2014144632A2 (en) 2014-09-18
PE20151923A1 (es) 2016-01-14
EA032830B1 (ru) 2019-07-31
MA38478A1 (fr) 2017-11-30
US9365653B2 (en) 2016-06-14
US10053507B2 (en) 2018-08-21
US20180094055A1 (en) 2018-04-05
ES2770976T3 (es) 2020-07-06
US9822178B2 (en) 2017-11-21
US10294298B2 (en) 2019-05-21
CR20150575A (es) 2016-01-06
AU2014228924A1 (en) 2015-10-01
BR112015023429A2 (pt) 2017-11-28
US20160251432A1 (en) 2016-09-01
EP2970470A2 (en) 2016-01-20
US20170247451A1 (en) 2017-08-31
EA201591791A1 (ru) 2016-03-31
IL241382A0 (en) 2015-11-30
US20180362645A1 (en) 2018-12-20
CA2906737C (en) 2023-08-15
WO2014144632A3 (en) 2014-11-20
CN105143267B (zh) 2020-06-26
BR112015023429A8 (pt) 2018-01-23
US20150010560A1 (en) 2015-01-08
TN2015000425A1 (en) 2017-01-03
PH12015502126A1 (en) 2016-01-25
HK1218554A1 (zh) 2017-02-24
KR102215405B1 (ko) 2021-02-10
HK1219958A1 (zh) 2017-04-21
SG11201507416WA (en) 2015-10-29
MX2015013181A (es) 2015-12-11
EP2970470B1 (en) 2019-12-04
CA2906737A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IL262804A (en) Antibodies to human pac1
CL2016001646A1 (es) Anticuerpos y fragmentos anti-vista
DK3336106T3 (da) Anti-fcrh5-antistoffer
DK2951203T3 (da) Heterodimere proteiner
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
DK3083688T3 (da) Humane anti-cd40 humane antistoffer
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3041857T3 (da) Protein a-kromatografi
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK3068800T3 (da) FcRn-specifikke antistoffer
DK2956698T5 (da) Bindestrimler
HK1219961A1 (zh) 人抗α型干擾素抗體
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
DK3065774T3 (da) Anti-CCL17-antistoffer
DK3071227T3 (da) Fiskevaccine
DE102013106534B8 (de) Chromatographiepipettenspitze
PL3016977T3 (pl) Ludzkie przeciwciała anty-IL-32
DE112014001252A5 (de) Aufbissschiene
FR3009951B1 (fr) Prothese intra-laryngee
DK3089990T3 (da) Forbedret proteinekspression
DK2981168T3 (da) Laminitiskile
DK3089991T3 (da) Forbedret proteinekspression